When she heard a couple of new, experimental drug to deal with pancreatic most cancers, Rachelle Gardner from Milwaukee within the United States tried to not get her hopes up.
She questioned: Would she be eligible for the treatment? Would her hospital be allowed to present it to her? Would she reside lengthy sufficient to get it?
In late July (2026), her questions have been answered.
In an examination room at City of Hope Cancer Center Chicago in Illinois, Gardner shook three gentle blue drugs out of a bottle, and sipping water, swallowed them one after the other.
“To good health and getting rid of that cancer bug!” she exclaimed cheerfully after downing the final capsule.
The 59-year-old trainer for college kids who’re visually impaired stated the treatment has given her “a new sense of hope”.
An various drug
Gardner is one in all dozens of sufferers in Illinois and throughout the US who, in current weeks, have began receiving the experimental treatment, which has been heralded as a breakthrough.
The drug, known as daraxonrasib, doesn’t remedy pancreatic most cancers, which is among the deadliest and most difficult-to-treat cancers.
But it offers many sufferers the subsequent neatest thing: extra time.
Typically, as soon as pancreatic most cancers spreads within the physique past the pancreas, sufferers could solely have months to reside.
But in a current medical trial the place the drug was given to sufferers with metastatic pancreatic most cancers who had already undergone a earlier remedy, the sufferers lived for a median of about 13 months after being enrolled within the examine, in contrast with a median of about six months for sufferers who had further chemotherapy as a substitute of daraxonrasib.
City of Hope Cancer Center Chicago medical oncologist Dr Evan Pisick known as it the largest advance in treating pancreatic most cancers in a long time.
“This is honestly a game-changer,” he stated.
“This is the thing that changes what we can offer patients.
“It’s the first targeted therapy we’re able to offer them, the first thing other than just giving chemotherapy.”
Expanded entry solely
The drug has not but been authorized by the US Food and Drug Administration (FDA), however the FDA is permitting drug producer Revolution Medicines to present the treatment to eligible sufferers with metastatic pancreatic most cancers who’ve already tried different therapies, below an expanded entry programme.
Physicians should submit requests for the treatment to Revolution for particular person sufferers.
The drug is supplied by the producer without charge to sufferers who’re a part of the expanded entry programme.
“It gives the patients an advantage to not have to sit around and wait because a lot of them don’t have that kind of time,” Dr Pisick stated of the expanded entry programme.
At City of Hope Cancer Center Chicago, Gardner is one in all seven or eight sufferers starting to obtain the drug, he stated.
Other Illinois well being methods which have began giving the treatment to sufferers in current weeks below the expanded entry programme embody Advocate Health Care, OSF HealthCare, Endeavor Health and University of Chicago Medicine.
Extending life
UChicago Medicine was additionally a medical trial website for the current examine of the treatment.
The drug’s means to elongate the lives of sufferers who’ve tried different therapies is “unprecedented in pancreatic cancer”, stated medical oncologist Dr Ardaman Shergill, who was the lead investigator for the medical trial at UChicago Medicine.
“In oncology, we are trying to help patients live longer,” she stated.
“If you can extend life, that is golden. That is the goal of treating metastatic diseases.”
Dr Shergill stated sufferers within the examine additionally reported that their ache, urge for food and vitality have been higher with daraxonrasib, in contrast with chemotherapy.
One of the sufferers who obtained the drug by means of UChicago Medicine, Mary Louise McAdams, 84, of Bronzeville, Chicago, stated she was initially instructed that she most likely had about six months to a 12 months to reside when she was identified with pancreatic most cancers in 2024.
She stated she underwent chemotherapy and radiation, however remedy was tough on her physique.
At one level, she stated she needed to be hospitalised due to negative effects.
When she realized she might get the brand new drug by means of the expanded entry programme, she thought it sounded promising and wished to present it a strive.
McAdams has now been on daraxonrasib for about two weeks.
“I hope I can prolong my life more.
“I don’t know how long, but rather than six months to a year longer, I’d like to live as long as possible, as long as I’m functional and able to contribute to my care somewhat.
“I’m looking forward to some more years of life with my children and grandchildren,” stated the mom of 5 and grandmother of 4.
From rash to most cancers
Gardner stated she by no means imagined three years in the past, when she was identified with pancreatic most cancers, {that a} new drug may assist her reside longer.
At that point, she didn’t realise something was amiss till she developed a wierd rash on her arms and chest.
An pressing care centre despatched her residence with prednisone and diphenhydramine to clear up the rash, she stated.
But the rash didn’t enhance and he or she developed jaundice, so she underwent extra testing that exposed issues along with her liver and gallbladder.
Ultimately, she was identified with stage 1 pancreatic most cancers.
She and her fiance have been sitting at their kitchen desk when she bought the decision.
“We looked at each other and started crying,” Gardner stated.
She stated she thought, “I’m just going to die now. What do we do?”
At a distinct hospital, Gardner underwent months of inauspicious chemotherapy after which a fancy surgical procedure known as the Whipple process, which includes eradicating the top of the pancreas, a part of the small gut, the gallbladder and the bile duct.
She stated she was then instructed to get extra chemotherapy, and at that time, determined to hunt opinions from different hospitals, together with City of Hope Cancer Center Chicago.
She was impressed with the hospital and Dr Pisick, and determined to remain.
For a time, there was no proof of the illness in her physique.
It held off till spring of 2025, when the most cancers got here again at Stage 4, she stated.
She started a distinct sort of chemotherapy and underwent radiation remedy earlier this 12 months (2026).
By May, nevertheless, docs instructed her that the chemotherapy and radiation would now not work for her.
“Basically, I’m going home for the cancer to beat me,” she stated.
“I’m like, ‘Nope, not going to do it.’”
Supporting her conviction was the information that City of Hope Cancer Center Chicago was making use of to get daraxonrasib for her and different sufferers.
Giving hope
Gardner’s expertise reveals the significance of medical analysis, stated Robert Stone, chief government officer of City of Hope, which has most cancers centres within the American states of Illinois, California, Georgia and Arizona.
“It takes so long, at times, to have therapies work their way through the regulatory system, and discovery is happening so fast that at times, (clinical trials and expanded access programmes) are the best treatment option for patients.
“And this is a perfect example,” he stated.
Now that Gardner has obtained the treatment – which needs to be taken day by day – she’s optimistic in regards to the 12 months to come back.
She hopes the drugs will give her extra time.
More time to go on highway journeys and check out new eating places along with her fiance.
More time to show.
More time to spend along with her two grown sons and her little grandnieces and grandnephews, who name her Auntie Gaga.
“There’s hope out there,” Gardner stated. – By Lisa Schencker/Chicago Tribune/Tribune News Service